Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 | ARDX Stock News

Apr 17, 2025

Ardelyx (ARDX, Financial) to announce Q1 2025 financial results on May 1, 2025.
Conference call scheduled for 4:30 p.m. Eastern Time.
Webcast replay available for 30 days post-call.

Ardelyx, Inc. (ARDX), a biopharmaceutical company focused on innovative medicine development, has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 4:30 p.m. Eastern Time. The call will cover detailed financial performance for Q1 2025 and include a business update.

Investors can participate in the conference call by dialing (877) 346-6112 for domestic calls or (848) 280-6350 for international calls. Additionally, a live audio webcast will be accessible in the Investors section of Ardelyx's website at www.ardelyx.com. The conference call will also be archived and available for replay for 30 days after the event.

Ardelyx, known for its significant contributions to the pharmaceutical sector, currently has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company continues to expand its international footprint through strategic agreements, including the commercialization of tenapanor for hyperphosphatemia in Japan with Kyowa Kirin, and recent approval in China with Fosun Pharma.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.